XML 61 R51.htm IDEA: XBRL DOCUMENT
v3.25.3

Collaborations and Other Arrangements (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | ---
Mar. 31, 2024 | Sep. 30, 2025 | Sep. 30, 2024 | Mar. 31, 2024 | Sep. 30, 2025 | Sep. 30, 2024 | Dec. 31, 2024
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |
Milestone payments, amount | $ 12,500 |  |  |  |  |  |
Research and development |  | $ 27,252 | $ 22,052 |  | $ 77,914 | $ 71,074 |
Junshi Biosciences |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |
Decrease in Research and Development Expenses for Release of Certain Liabilities |  |  |  | $ 4,800 |  |  |
Research and development |  | 0 | $ 0 |  | 0 | $ 0 |
Royalties due |  | $ 2,200 |  |  | $ 2,200 |  | $ 1,500
Junshi Biosciences | Intangible assets, net and accrued and other current liabilities |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |
Accrued milestone payment | $ 25,000 |  |  | $ 25,000 |  |  |
Junshi Biosciences | Accrued and other current liabilities |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |
Co-development, regulatory and technology transfer costs |  |  |  |  |  |  | 12,500
Junshi Biosciences | Accounts payable |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions |  |  |  |  |  |  |
Co-development, regulatory and technology transfer costs |  |  |  |  |  |  | $ 400

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for milestone payments. + References No definition available. + Details
Name: | chrs_AccruedMilestonePayment
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents co-development, regulatory and technology transfer costs. + References No definition available. + Details
Name: | chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of decrease in research and development expenses for release of certain liabilities. + References No definition available. + Details
Name: | chrs_DecreaseInResearchAndDevelopmentExpensesForReleaseOfCertainLiabilities
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount per each installment of milestone payments under collaborative arrangements. + References No definition available. + Details
Name: | chrs_MilestonePaymentsAmountPerEachInstallment
Namespace Prefix: | chrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details
Name: | us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=chrs_AccruedAndOtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |